Life science REIT — DCF P(above)=82.3% with FV=$57 strongly supportive. Lab/office demand has been weak post-COVID but thesis intact for long-term lab space supply constraints. Target divergence (old $22.50 vs FV $57) suggests stale data. Upgrade to neutral pending fresh analysis.
Fair Value Distribution — percentile bands
89.2% of simulations place fair value above current price
WHAT IS PRICED IN
Revenue-Based Reverse DCF
-1.2%/yr
±3.3% · revenue growth to justify current price
FCF-Based Reverse DCF
6.1%/yr
±2.6% · FCF growth to justify current price
THE GAP
Market pricing margin compression or rising capex
KEY VALUE DRIVERS
Spearman correlation — what moves this valuation most
Eagle will generate this view by the next trading session (~6h).
Eagle will generate this view by the next trading session (~6h).
ARE 10-K shows headwinds: occupancy 90.9% vs 95% 10yr avg, 45% dividend cut signals confidence loss. Tenant funding constraints post-SVB, construction cost inflation, 3.5M RSF execution risk. Concentr...